Innoviva, Inc.

Innoviva reported a mixed financial performance for the first half of 2026, with net income soaring to $103.2 million, a 503% increase year-over-year. However, the second quarter of 2026 saw a net loss of $(83.4) million, primarily due to negative fair value adjustments on equity and long-term investments. Total revenue for Q2 increased by 19.2% to $119.6 million, driven by a 45.9% rise in net product sales. The company also noted the FDA approval of NUZOLVENCE® in December 2025, with commercial availability expected in the second half of 2026, and repurchased $51.3 million in common stock during H1.

Innoviva, Inc. reported strong financial results for the second quarter ended June 30, 2026, with total revenue increasing 19% year-over-year to $119.6 million and net product sales growing 46% to $51.8 million. Despite operational strength, the company recorded a net loss of $83.4 million, primarily driven by $161.0 million in unfavorable fair value changes in equity and long-term investments. Strategically, Innoviva launched Nortiva Bio, a new wholly-owned subsidiary focused on novel extended-release drug delivery, and entered a licensing agreement with Dr. Reddy’s Laboratories for XACDURO® in emerging markets. The company also continued its share repurchase program, buying back $31.4 million in shares during the quarter.

Innoviva, Inc. announced the resignations of Derek Small and Mark DiPaolo from its Board of Directors on May 12, 2026. Their departure was to concentrate on Syndeio BioSciences Inc., a company Innoviva has invested in. The company subsequently elected Josephine Linden to the Board on May 18, 2026. Mrs. Linden, a seasoned investment professional and former Goldman Sachs Partner, will serve as an independent director and is expected to join the Audit Committee. Her compensation includes RSU awards totaling $331,250 and options for 9,166 shares.

Innoviva reported a significant turnaround in its first quarter 2026 financial results, swinging to a net income of $186.6 million, compared to a net loss of $46.6 million in the prior year period. Total revenue increased by 10.6% to $98.0 million, driven by a substantial 36.6% growth in net product sales, particularly from XACDURO®. The positive financial performance was also significantly boosted by favorable changes in the fair values of equity method and long-term investments. The company also announced the FDA approval of NUZOLVENCE® in December 2025, with availability expected in the second half of 2026.

Innoviva reported a strong start to 2026, with total revenue increasing 11% to $98.0 million and net income reaching $186.6 million for the first quarter. This performance was driven by resilient royalty revenue and significant growth in net product sales, particularly from its Innoviva Specialty Therapeutics (IST) platform. The company also highlighted the FDA approval of NUZOLVENCE and active capital allocation, including share repurchases, underscoring confidence in its long-term value proposition.